SignalFDA/Bio

XENON PHARMACEUTICALS INC. (XENE) DISCUSSES AZETUKALNER NDA SUBMISSION FOR FOCAL SEIZURES AND PSYCHIATRY PROGRAM UPDATE TRANSCRIPT - SEEKINGALPHA

Azetukalner NDA submission for focal seizures and psychiatry program update drive biotech catalyst relevance.

What changed

Azetukalner NDA submission for focal seizures and psychiatry program update drive biotech catalyst relevance.

Why it matters

Azetukalner NDA submission for focal seizures and psychiatry program update drive biotech catalyst relevance. — impact context not separately stored; see What changed.

Sources

seekingalpha